FXR Agonists for Reducing LOX-1 Expression

摘要

Provided are certain methods of treating at least one disease state characterized by elevated expression of the Lectin-like Oxidized Low-density Lipoprotein Receptor 1 (LOX-1) in a patient with farnesoid X receptor agonists. Also provided are certain methods of reducing expression of LOX-1 in a cell with farnesoid X receptor agonists.